| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Operating activities: | ||||||
Net loss | ||||||
66,858 | -164,981 | -68,357 | -23,202 | |||
Reconciliation of net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
4,725 | 3,519 | 3,024 | 925 | |||
Equity-based compensation | ||||||
44,057 | 34,985 | 18,873 | 10,844 | |||
Loss from equity method investment | ||||||
-5,467 | -4,275 | -1,763 | -36,380 | |||
Non-cash interest | ||||||
- | - | - | 8,050 | |||
Unrealized foreign currency remeasurement (gain) loss | ||||||
- | - | - | -2 | |||
Gain on extinguishment of convertible loan | ||||||
- | - | - | 11,482 | |||
Other income - formation of joint venture | ||||||
- | - | - | 78,608 | |||
Non-cash expense related to ViaCyte transaction | ||||||
- | 15,582 | - | - | |||
Gain from consolidation of Casebia | ||||||
16,000 | - | - | - | |||
Other income, non-cash | ||||||
- | 169 | 9 | - | |||
Changes in: | ||||||
Accounts receivable | ||||||
11 | -2,538 | -531 | 2,818 | |||
Prepaid expenses and other assets | ||||||
32,618 | 3,342 | 4,117 | 1,071 | |||
Accounts payable and accrued expenses | ||||||
5,025 | 12,110 | -831 | 3,860 | |||
Deferred revenue | ||||||
-45,146 | -296 | -20,718 | 1,917 | |||
Deferred rent | ||||||
- | -709 | -522 | 2,360 | |||
Operating lease assets and liabilities | ||||||
-663 | - | - | - | |||
Other liabilities, net | ||||||
24,983 | 249 | 270 | -17 | |||
Net cash used in operating activities | ||||||
56,677 | -96,239 | -70,093 | -52,860 | |||
Purchase of property and equipment | ||||||
6,684 | 2,773 | 7,814 | 3,016 | |||
Net cash and restricted cash received in connection with the acquisition of Casebia | ||||||
8,009 | - | - | - | |||
Proceeds from contribution of intellectual property to equity method investee | ||||||
- | - | - | 35,000 | |||
Cash investment in equity method investee | ||||||
- | - | - | 100 | |||
Purchase of available for sale debt security | ||||||
- | - | 500 | - | |||
Net cash used in investing activities | ||||||
1,325 | -2,773 | -8,314 | 31,884 | |||
Proceeds from issuance of common shares, net of issuance costs | ||||||
415,019 | 307,053 | - | 89,061 | |||
Proceeds from exercise of options, net of issuance costs | ||||||
15,964 | 8,938 | 2,608 | 34 | |||
Repurchase of treasury shares | ||||||
- | 57 | - | - | |||
Issuance costs for preferred share financings | ||||||
- | - | - | 1,810 | |||
Proceeds from issuance of convertible loans | ||||||
- | - | - | 35,010 | |||
Net cash provided by financing activities | ||||||
430,983 | 315,934 | 2,608 | 183,220 | |||
Effect of exchange rate changes on cash | ||||||
15 | -22 | 41 | -235 | |||
Decrease in cash | ||||||
489,000 | 216,900 | -75,758 | 162,009 | |||
Supplemental disclosure of non-cash investing and financing activities | ||||||
Property and equipment purchases in accounts payable and accrued expenses | ||||||
1,811 | 334 | - | 7,014 | |||
Stock option issuance costs included in accrued expenses | ||||||
295 | 375 | - | - | |||
Costs for proposed supplemental offering in accounts payable and accrued expenses | ||||||
- | - | 290 | - | |||
Property and equipment related to lease incentives | ||||||
- | - | - | 10,785 | |||
Conversion of preferred shares to common shares upon IPO | ||||||
- | - | - | 185,565 | |||
Conversion of Vertex and Bayer convertible loans and accrued interest | ||||||
- | - | - | 61,929 | |||
Issuance costs for public offering in accounts payable and accrued expenses | ||||||
- | - | - | 397 | |||
Contribution of intellectual property to Casebia | ||||||
- | - | - | 36,380 | |||
Series A-3 Redeemable Convertible Preferred Shares [Member] | ||||||
Proceeds from issuance of preferred shares | ||||||
- | - | - | 22,850 | |||
Series B Redeemable Convertible Preferred Shares [Member] | ||||||
Proceeds from issuance of preferred shares | ||||||
- | - | - | 38,075 | |||